Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study

Authors: Yingchun Zeng, Andy S. K. Cheng, Ting Song, Xiujie Sheng, Yang Zhang, Xiangyu Liu, Chetwyn C. H. Chan

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Subjective cognitive impairment can be a significant and prevalent problem for gynaecological cancer survivors. The aims of this study were to assess subjective cognitive functioning in gynaecological cancer survivors after primary cancer treatment, and to investigate the impact of cancer treatment on brain structural networks and its association with subjective cognitive impairment.

Methods

This was a cross-sectional survey using a self-reported questionnaire by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) to assess subjective cognitive functioning, and applying DTI (diffusion tensor imaging) and graph theoretical analyses to investigate brain structural networks after primary cancer treatment.

Results

A total of 158 patients with gynaecological cancer (mean age, 45.86 years) and 130 age-matched non-cancer controls (mean age, 44.55 years) were assessed. Patients reported significantly greater subjective cognitive functioning on the FACT-Cog total score and two subscales of perceived cognitive impairment and perceived cognitive ability (all p values <0.001). Compared with patients who had received surgery only and non-cancer controls, patients treated with chemotherapy indicated the most altered global brain structural networks, especially in one of properties of small-worldness (p = 0.004). Reduced small-worldness was significantly associated with a lower FACT-Cog total score (r = 0.412, p = 0.024). Increased characteristic path length was also significantly associated with more subjective cognitive impairment (r = −0.388, p = 0.034).

Conclusion

When compared with non-cancer controls, a considerable proportion of gynaecological cancer survivors may exhibit subjective cognitive impairment. This study provides the first evidence of brain structural network alteration in gynaecological cancer patients at post-treatment, and offers novel insights regarding the possible neurobiological mechanism of cancer-related cognitive impairment (CRCI) in gynaecological cancer patients. As primary cancer treatment can result in a more random organisation of structural brain networks, this may reduce brain functional specificity and segregation, and have implications for cognitive impairment. Future prospective and longitudinal studies are needed to build upon the study findings in order to assess potentially relevant clinical and psychosocial variables and brain network measures, so as to more accurately understand the specific risk factors related to subjective cognitive impairment in the gynaecological cancer population. Such knowledge could inform the development of appropriate treatment and rehabilitation efforts to ameliorate cognitive impairment in gynaecological cancer survivors.
Literature
1.
go back to reference Craig CD, Monk BJ, Farley JH, Chase DM. Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment. Support Care Cancer. 2014;22:279–87.CrossRefPubMed Craig CD, Monk BJ, Farley JH, Chase DM. Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment. Support Care Cancer. 2014;22:279–87.CrossRefPubMed
2.
go back to reference Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65:123–38.CrossRefPubMed Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65:123–38.CrossRefPubMed
3.
go back to reference Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102–13.CrossRefPubMedPubMedCentral Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102–13.CrossRefPubMedPubMedCentral
4.
go back to reference Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of cancer and its treatment on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manag. 2015;50(6):830–41.CrossRef Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of cancer and its treatment on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manag. 2015;50(6):830–41.CrossRef
5.
go back to reference Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol. 2012;124(3):404–9.CrossRefPubMed Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol. 2012;124(3):404–9.CrossRefPubMed
6.
go back to reference Hess LM, Huang HQ, Hanlon AL, Robinson WR, Johnson R, Chambers SK, et al. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;139(3):541–5.CrossRefPubMedPubMedCentral Hess LM, Huang HQ, Hanlon AL, Robinson WR, Johnson R, Chambers SK, et al. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;139(3):541–5.CrossRefPubMedPubMedCentral
7.
go back to reference Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–6.CrossRefPubMed Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–6.CrossRefPubMed
8.
go back to reference Amidi A, Wu LM, Pedersen AD, Mehlsen M, Pedersen CG, Rossen P, et al. Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment. Support Care Cancer. 2015a;23(10):2973–9.CrossRefPubMed Amidi A, Wu LM, Pedersen AD, Mehlsen M, Pedersen CG, Rossen P, et al. Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment. Support Care Cancer. 2015a;23(10):2973–9.CrossRefPubMed
9.
go back to reference Amidi A, Christensen S, Mehlsen M, Jensen AB, Pedersen AD, Zachariae R. Long-term subjective cognitive functioning following adjuvant systemic treatment: 7–9 years follow-up of a nationwide cohort of women treated for primary breast cancer. Br J Cancer. 2015b;113(5):794–801. doi:10.1038/bjc.2015.243.CrossRefPubMedPubMedCentral Amidi A, Christensen S, Mehlsen M, Jensen AB, Pedersen AD, Zachariae R. Long-term subjective cognitive functioning following adjuvant systemic treatment: 7–9 years follow-up of a nationwide cohort of women treated for primary breast cancer. Br J Cancer. 2015b;113(5):794–801. doi:10.​1038/​bjc.​2015.​243.CrossRefPubMedPubMedCentral
10.
go back to reference Amidi A, Hadi Hosseini SM, Leemans A, Kesler SR, Agerbæk M, Wu LM, Zachariae R. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. JNCI J Natl Cancer Inst. 2017;109(12):djx085.CrossRef Amidi A, Hadi Hosseini SM, Leemans A, Kesler SR, Agerbæk M, Wu LM, Zachariae R. Changes in brain structural networks and cognitive functions in testicular cancer patients receiving cisplatin-based chemotherapy. JNCI J Natl Cancer Inst. 2017;109(12):djx085.CrossRef
11.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA: Ca J Clin. 2016;66:115–32. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA: Ca J Clin. 2016;66:115–32.
12.
go back to reference Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105:791–801.CrossRefPubMedPubMedCentral Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105:791–801.CrossRefPubMedPubMedCentral
13.
go back to reference Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent RA, Yap YS, Lo SK, Ng RC, Chan A. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother. 2012;46(12):1645–55.CrossRefPubMed Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent RA, Yap YS, Lo SK, Ng RC, Chan A. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother. 2012;46(12):1645–55.CrossRefPubMed
14.
go back to reference Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, Reneman L, Schagen SB, Multimodal MRI. Cognitive function in patients with breast cancer prior to adjuvant treatment--the role of fatigue. Neuroimage Clin. 2015;7:547–54.CrossRefPubMedPubMedCentral Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, Reneman L, Schagen SB, Multimodal MRI. Cognitive function in patients with breast cancer prior to adjuvant treatment--the role of fatigue. Neuroimage Clin. 2015;7:547–54.CrossRefPubMedPubMedCentral
15.
go back to reference Amidi A, LM W, Agerbaek M, et al. Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. Psychooncology. 2015c;24(9):1174–80.CrossRefPubMed Amidi A, LM W, Agerbaek M, et al. Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. Psychooncology. 2015c;24(9):1174–80.CrossRefPubMed
16.
go back to reference Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35:506–14.CrossRef Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35:506–14.CrossRef
17.
go back to reference Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, Dodd A, Crawley A, Tannock IFA. Mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2017; in press; doi:10.1007/s11682-017-9728-5. Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, Dodd A, Crawley A, Tannock IFA. Mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2017; in press; doi:10.​1007/​s11682-017-9728-5.​
18.
go back to reference Kesler SR, Gugel M, Huston-Warren E, Watson C. Atypical structural Connectome organization and cognitive impairment in young survivors of acute lymphoblastic leukemia. Brain Connect. 2016;6(4):273–82.CrossRefPubMedPubMedCentral Kesler SR, Gugel M, Huston-Warren E, Watson C. Atypical structural Connectome organization and cognitive impairment in young survivors of acute lymphoblastic leukemia. Brain Connect. 2016;6(4):273–82.CrossRefPubMedPubMedCentral
19.
go back to reference Achard S, Salvador R, Whitcher B, Suckling J, Bullmore EA. Resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. J Neurosci. 2006;26:63–72.CrossRefPubMed Achard S, Salvador R, Whitcher B, Suckling J, Bullmore EA. Resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. J Neurosci. 2006;26:63–72.CrossRefPubMed
20.
21.
go back to reference Catani M, Dell’acqua F, Bizzi A, Forkel SJ, Williams SC, Simmons A, Murphy DG. Thiebaut de Schotten M. Beyond cortical localization in clinico-anatomical correlation. Cortex. 2012;48:1262–87.CrossRefPubMed Catani M, Dell’acqua F, Bizzi A, Forkel SJ, Williams SC, Simmons A, Murphy DG. Thiebaut de Schotten M. Beyond cortical localization in clinico-anatomical correlation. Cortex. 2012;48:1262–87.CrossRefPubMed
22.
go back to reference Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging. 2015;36(8):2429–42.CrossRefPubMedPubMedCentral Kesler SR, Watson CL, Blayney DW. Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer. Neurobiol Aging. 2015;36(8):2429–42.CrossRefPubMedPubMedCentral
23.
go back to reference Wagner L, Sweet J, Butt Z, et al. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7:W32–9. Wagner L, Sweet J, Butt Z, et al. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7:W32–9.
24.
go back to reference Zigmond AS, Snaith RP. The HADS: Hospital Anxiety and Depression Scale. Windsor 1994: NFER Nelson. Zigmond AS, Snaith RP. The HADS: Hospital Anxiety and Depression Scale. Windsor 1994: NFER Nelson.
25.
go back to reference Lu C, Ding H, Le J, Yu Q, Liu B. An investigation of quality of life of post-surgical patients with Cephalocevical cancer. Chin Nurs Res. 2004;18:5–7. [in Chinese] Lu C, Ding H, Le J, Yu Q, Liu B. An investigation of quality of life of post-surgical patients with Cephalocevical cancer. Chin Nurs Res. 2004;18:5–7. [in Chinese]
26.
go back to reference Nian S. Investigation of the quality of life among lung cancer patients pre-and post-chemotherapy. Master Thesis, Zhejiang University 2012. [in Chinese]. Nian S. Investigation of the quality of life among lung cancer patients pre-and post-chemotherapy. Master Thesis, Zhejiang University 2012. [in Chinese].
27.
go back to reference Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients. Cancer. 1999;85(5):1186–96.CrossRefPubMed Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients. Cancer. 1999;85(5):1186–96.CrossRefPubMed
28.
go back to reference Dimeo F, Schwartz S, Wesel N, Voigt A, Thiel E. Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment. Ann Oncol. 2008;19(8):1495–9.CrossRefPubMed Dimeo F, Schwartz S, Wesel N, Voigt A, Thiel E. Effects of an endurance and resistance exercise program on persistent cancer-related fatigue after treatment. Ann Oncol. 2008;19(8):1495–9.CrossRefPubMed
29.
go back to reference Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111–8.CrossRefPubMed Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111–8.CrossRefPubMed
30.
go back to reference Tabachnik BG, Fidell LS. Using multivariate statistics. 6th ed. Boston: Pearson; 2013. Tabachnik BG, Fidell LS. Using multivariate statistics. 6th ed. Boston: Pearson; 2013.
31.
go back to reference Irfanoglu MO, Walker L, Sarlls J, Marenco S, Pierpaoli C. Effects of image distortions originating from susceptibility variations and concomitant fields on diffusion MRI tractography results. NeuroImage. 2012;61(1):275–88.CrossRefPubMed Irfanoglu MO, Walker L, Sarlls J, Marenco S, Pierpaoli C. Effects of image distortions originating from susceptibility variations and concomitant fields on diffusion MRI tractography results. NeuroImage. 2012;61(1):275–88.CrossRefPubMed
32.
go back to reference Cui Z, Zhong S, Xu P, He Y, Gong G. PANDA: a pipeline toolbox for analyzing brain diffusion images. Front Hum Neurosci. 2013;7:42.PubMedPubMedCentral Cui Z, Zhong S, Xu P, He Y, Gong G. PANDA: a pipeline toolbox for analyzing brain diffusion images. Front Hum Neurosci. 2013;7:42.PubMedPubMedCentral
33.
go back to reference Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GRETNA: a graph theoretical network analysis toolbox for imaging connectomics. Front Hum Neurosci. 2015;9:386.PubMedPubMedCentral Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GRETNA: a graph theoretical network analysis toolbox for imaging connectomics. Front Hum Neurosci. 2015;9:386.PubMedPubMedCentral
34.
go back to reference Von AD, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. J Pain Symptom Manag. 2015;49:697–706.CrossRef Von AD, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. J Pain Symptom Manag. 2015;49:697–706.CrossRef
35.
go back to reference Zeng YC, Cheng ASK, Feuerstein M. Symptom profiles, work productivity and quality of life among Chinese breast and cervical cancer survivors. Gynecol Obst. 2016;6:357. Zeng YC, Cheng ASK, Feuerstein M. Symptom profiles, work productivity and quality of life among Chinese breast and cervical cancer survivors. Gynecol Obst. 2016;6:357.
36.
go back to reference Van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, Donovan HS, Thurston RC, Morse JQ, Nutt S, Rechis R. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer. 2014;22:937–45.CrossRefPubMed Van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, Donovan HS, Thurston RC, Morse JQ, Nutt S, Rechis R. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer. 2014;22:937–45.CrossRefPubMed
37.
go back to reference Van Dyk K, Ganz PA. Doctor, now that my chemotherapy treatment is over, when will my “Chemofog” lift? J Clin Oncol. 2017;35(5):482–4.CrossRef Van Dyk K, Ganz PA. Doctor, now that my chemotherapy treatment is over, when will my “Chemofog” lift? J Clin Oncol. 2017;35(5):482–4.CrossRef
38.
go back to reference Kim J, Parker D, Whyte J, et al. Disrupted structural connectome is associated with both psychometric and real-world neuropsychological impairment in diffuse traumatic brain injury. J Int Neuropsychol Soc. 2014;20(9):887–96.CrossRefPubMedPubMedCentral Kim J, Parker D, Whyte J, et al. Disrupted structural connectome is associated with both psychometric and real-world neuropsychological impairment in diffuse traumatic brain injury. J Int Neuropsychol Soc. 2014;20(9):887–96.CrossRefPubMedPubMedCentral
39.
40.
go back to reference Latora V, Marchiori M. Efficient behavior of small-world networks. Phys Rev Lett. 2001;87(19):198701.CrossRefPubMed Latora V, Marchiori M. Efficient behavior of small-world networks. Phys Rev Lett. 2001;87(19):198701.CrossRefPubMed
Metadata
Title
Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study
Authors
Yingchun Zeng
Andy S. K. Cheng
Ting Song
Xiujie Sheng
Yang Zhang
Xiangyu Liu
Chetwyn C. H. Chan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3793-4

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine